PEAK1, a Novel Kinase Target in the Fight Against Cancer by Kelber, Jonathan A. & Klemke, Richard L.
 
www.impactjournals.com/oncotarget/             Oncotarget, July 2010, Vol. 1, No 3 
 
  
www.impactjournals.com/oncotarget    219      Oncotarget 2010; 1: 219-223 
 
INTRODUCTION 
 
The completion of the human genome has enabled 
the identification of almost all protein kinase genes 
(approximately 518 total). While this number is less 
than originally predicted [1], it constitutes almost 2% 
of the entire human genome [2]. Because kinases are 
integral to almost all signaling processes in eukaryotic 
cells via their role as posttranslational modifiers, it is 
crucial to identify and characterize their molecular and 
functional properties in order to more fully understand 
human physiology and disease. For example, kinases 
play central roles in cellular processes ranging from 
cell-cycle progression to cell motility to cell 
differentiation, and their proper function controls 
development and homeostasis in the adult [3-8]. 
Additionally, dysregulation of kinase genes accounts 
for the origin of many human diseases, making them an 
important family of genes to comprehensively 
understand - possibly leading to novel therapeutic 
approaches for fighting multiple pathologies [9-13]. 
Well known kinases, such as Src, MAPK and, ErbB2 
have well established roles during development and 
cancer progression. Critical insights into their functions 
and mechanisms of action have led to important 
therapeutic strategies for fighting cancer [5]. Therefore, 
since a significant number of novel kinases (71) remain 
unconfirmed at the protein level [2], it is important to 
gain a more complete functional understanding of the 
human kinome. Furthermore, many of these are likely 
to contribute to cancer and provide novel therapeutic 
targets to circumvent the side effects of current 
chemical and radiation therapies or the acquired 
resistance to more specific therapies. 
Over the past decade, our lab has developed a 
number of new approaches for studying the role of the 
cellular cytoskeleton and the subcellular domains that it 
regulates during cell migration, neurogenesis and 
cancer progression [14-22]. More specifically, we have 
developed a unique method to purify and characterize 
cell pseudopodia using a 3.0 μm porous membrane 
system. When attached to the top of these membranes 
and subjected to a chemoattractant, cells begin to 
protrude their pseudopodia through these pores - they 
can then be mechanically isolated from the remainder 
of the cell body [19-21]. We used these unique 
approaches to probe the proteome and 
phosphoproteome of these subcellular structures. Our 
ability to affinity purify pY proteins from isolated 
pseudopodia proved to be a robust system to identify 
proteins involved in cell migration. Also, the complete 
solublization of pseudopodial proteins in SDS buffer 
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Fig. 1: A schematic showing PEAK1 actin-targeting and kinase domains as well as the predicted binding or 
substrate residues for Src, Erk, Crk and Shc proteins. 
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significantly improved our yield of pY proteins, which 
can be tightly associated with the insoluble 
cytoskeleton [23]. This approach allowed us to identify 
many low abundance pY proteins involved in cell 
migration and led to the discovery of the 
phosphotyrosine protein and kinase, PEAK1 
(pseudopodium-enriched atypical kinase 1, KIAA2002, 
sgk269). Collectively, our findings demonstrate that 
PEAK1 is a new non-receptor tyrosine kinase that 
operates within Src-p130Cas-Crk-Paxillin and Ras-
Raf-Erk signaling pathways to regulate cell 
proliferation, migration and cancer progression [24] 
(Table 1). 
PEAK1 is a member of the new kinase family three 
(NKF3) and its domain structure is complex, with 
predicted consensus binding and/or substrate sites for 
Src, Erk, Shc  and Crk. Notably, PEAK1 is 
ubiquitously expressed in multiple tissues, suggesting 
that it has a major role in normal physiology [24]. In 
addition, we determined that PEAK1 contains an N-
terminal actin-targeting region and a functional C-
terminal atypical kinase domain (Figure 1). All active 
kinases are predicted to contain three motifs VAIK, 
HRD, and DFG within the kinase domain [2]. Each 
motif contains one highly conserved residue (VAIK: 
K, HRD: D, DFG: D) that is predicted to be important 
for full catalytic activity. Sequence analysis revealed 
that PEAK1 contains all three motifs YAVK, HCD, 
and NFS. While the YAVK and HCD motifs are highly 
conserved on the critical K and D residues, the D 
residue in the NFS motif is replaced by N, which 
classifies it as an atypical kinase [2]. However, little is 
known about whether this amino acid substitution can 
affect kinase catalytic activity or whether this PEAK1 
residue (and/or others) may be mutated in human 
cancers to confer full catalytic activity [2]. While we 
were initially able to demonstrate tyrosine kinase 
activity in the full-length protein that had been 
immunoaffinity purified from mammalian cells, this 
did not remove the possibility that other tyrosine 
kinases bind and co-precipitate with PEAK1, 
accounting for the detected activity. To address this 
possibility, we generated a C-terminal construct that 
included the kinase domain (a.a. 1289-1746) that was 
expressed in and purified from E. coli. Notably, this 
allowed us to generate large amounts of the purified 
PEAK1 truncation mutant, and it also displayed 
intrinsic tyrosine kinase activity in vitro [24]. 
In agreement with PEAK1 containing an actin-
targeting region, modulation of PEAK1 protein levels 
affected the phosphorylation level of several known 
cytoskeletal regulatory proteins including paxillin, 
p130Cas and Erk, and it was found to associate with 
the Crk adaptor protein. Crk regulates cell spreading 
Table 1: Summary of known PEAK1 functions. NT = not tested.  
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and migration by coupling critical signaling proteins 
such as EGFR, ErbB2, PDGFR, C-Abl and p130Cas to 
the cytoskeleton and focal adhesions [25]. p130Cas and 
its family members are necessary for cell migration and 
cancer progression in vitro and in vivo [26-28]. The 
Src-p130Cas-Crk complex has been shown to modulate 
Rac activity, pseudopodium protrusion, cell migration 
and cancer progression [27-30]. We have also shown 
that Src is necessary for growth factor- and integrin-
induced tyrosine phosphorylation of PEAK1 [24]. 
Together, these findings suggest that integrins and 
growth factors may cooperate to activate Src, which in 
turn phosphorylates p130Cas on Y165, Y249, or Y410 
leading to Crk binding through its SH2 domain. Via its 
association with the SH3 domain of Crk, we predict 
that PEAK1 assists in the recruitment of Crk to the Src-
p130Cas-Crk scaffold. PEAK1's subsequent 
phosphorylation by Src on Y665 may function to 
facilitate its cytoskeletal or focal adhesion localization 
and/or its kinase activation. It is very likely that these 
PEAK1-mediated molecular interactions are critical for 
the proper dynamic rearrangement of the actin 
cytoskeleton and focal adhesions during cell migration, 
as cells undergo a significant reduction in their 
migratory potential when depleted of PEAK1 protein 
[24]. It will be important for future studies to 
characterize the role of PEAK1 during early, 
proliferative versus late, metastatic stages of cancer 
progression. Nevertheless, PEAK1 likely fulfills 
several important molecular functions. First, it may 
modulate protein-protein interactions by directly 
phosphorylating components of the Src-p130Cas-Crk 
scaffold via its tyrosine kinase activity. Second, given 
that PEAK1 translocates to focal adhesions and the 
actin cytoskeleton, it could provide a mechanism to 
transport the Src-p130Cas-Crk scaffold to these 
structures. Finally, it may deliver unique effector 
proteins to these cytoskeletal structures, which in turn 
may regulate cell migration and/or proliferation. In any 
case, our observations that PEAK1 can interact with 
and modulate the Src-p130Cas-Crk-Paxillin and Ras-
Raf-Erk pathways downstream of integrins and 
receptor tyrosine kinases (RTKs) point to a central role 
for this novel tyrosine kinase during cell migration and 
proliferation in normal and transformed cells [24]. 
Although we are the first to clone and directly study 
the function of PEAK1, several independent lines of 
evidence also suggest that PEAK1 and its only family 
member sgk223 (pragmin) (33% overall homology to 
PEAK1) play integral roles in regulating cell motility 
and tumor progression [31-32]. For example, sgk223 
Fig. 2: A model depicting the role of PEAK1 in 
mediating signaling events through the Src-
p130Cas-Crk and Ras-Raf-Erk signaling 
pathways downstream of receptor tyrosine 
kinases (RTKs) and integrins. It is likely that 
PEAK1 has both scaffolding and catalytic 
functions in these pathways. 
Predicted PEAK1-mediated steps during 
RTK- or Integrin-induced tumor progression:  
 
1)  Ligand/RTK- or Integrin-induced binding of 
activated Src (Y416).  
2)  Src-mediated tyrosine phosphorylation of 
p130Cas (Y165, Y249, Y410, etc.).  
3)  Binding of Crk (SH3 domain) to PEAK1 
(P1153) and recruitment of the PEAK1/Crk 
complex to phospho-p130Cas - PEAK1 
enables multiple Crk molecules to bind to 
multiple phosphotyrosine residues on 
p130Cas. Enhanced Crk activation and 
binding to DOCK180 leads to Rac1 activation, 
membrane protrusion and cell migration.  
4)  Src-mediated tyrosine phosphorylation of 
PEAK1 (Y665) leads to enhanced and/or 
sustained Src phosphorylation (Y416) and 
activation (possibly through PEAK1 tyrosine 
kinase activity) - this further enhances 
130Cas/Crk coupling and the subsequent 
signaling events downstream of Crk 
activation.  
5)  PEAK1 may also promote cell proliferation 
and migration through the Ras/Raf/Erk 
pathway downstream of RTKs and Integrins, 
via its predicted Erk binding (P228) and 
substrate (S779/T783) sites. 
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has been reported to be a novel effector of Rnd2 
GTPase, and has also been shown to stimulate RhoA 
activity in HeLa cells and mediate cancer cell invasion 
in a Src-dependent manner [32]. More recently, sgk223 
and PEAK1 were both identified in a quantitative 
phosphoproteomics study as potential targets that 
mediate Src-induced invasion in advanced colon 
carcinoma cells [31]. We have recently demonstrated 
that PEAK1 promotes proliferation, migration and 
anchorage-independent growth in vitro and tumor 
formation in vivo [24]. While large shRNA genomic 
screens have suggested that PEAK1 is involved in 
cancer cell proliferation [33], our recent report is the 
first to directly link PEAK1 function with cancer 
progression and demonstrate that PEAK1 levels are 
amplified in over 80% of colon cancer patients 
(primary and metastatic lesions). Notably, this 
underscores the importance of understanding the role 
of PEAK1 in human cancers (Table 1). 
While it is clear now that PEAK1 has intrinsic 
tyrosine kinase activity in vitro, future studies should 
probe the role of its kinase domain during tumor 
progression and identify potential substrates of this 
novel cytoskeleton-associated kinase. More 
comprehensive mechanistic studies are also warranted 
in order to more completely understand how PEAK1 
couples to multiple intracellular signaling pathways 
and the actin cytoskeleton or focal adhesions to 
promote cell proliferation and motility. Specifically, it 
will be crucial to elucidate the differential roles for 
PEAK1 in the Src-p130Cas-Crk-Paxillin and Ras-Raf-
Erk signaling pathways. Finally, understanding the 
upstream regulators of PEAK1 and why it is 
upregulated in human colon cancers (and whether it is 
also upregulated in other human cancers) will likely 
help clinical oncologists understand disease 
progression. Importantly, PEAK1 is a critical regulator 
of multiple cellular processes and its tyrosine kinase 
domain may likely provide a novel therapeutic target 
for controlling aberrant cellular functions that lead to 
cancer. 
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